Rapid and Reproducible Karyotyping with Long Read Sequencing in AML Patients
Open Access
- 25 June 2026
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (19) , 6774-6784
Abstract
Acute myeloid leukemia (AML) is characterized by recurrent chromosomal abnormalities that form the basis of the European LeukemiaNet (ELN) risk classification and serve as essential determinants of prognosis and therapeutic decision-making. Conventional metaphase karyotyping remains the diagnostic gold standard for detecting these abnormalities; however, its utility is limited by longer turnaround times, often delaying critical clinical management. Here, we present a long-read sequencing-based (LRS) low-coverage whole genome sequencing (lcWGS) approach using Oxford Nanopore Technology as a rapid and scalable alternative for cytogenetic profiling. A total of 100 diagnostic AML samples were analyzed, comprising 50 retrospectively selected cases with known adverse-risk cytogenetics and 50 prospectively enrolled patients with clinically defined de novo AML. LcWGS demonstrated robust analytical performance, identifying chromosomal aberrations with 93% sensitivity, specificity, and overall accuracy, respectively. Complex karyotypes were reliably detected, with an area under the curve (AUC) of 0.971. Reproducibility was validated through replicate sequencing at two independent laboratories (R=0.99). LcWGS-derived estimates of clone size showed moderate correlation with conventional cytogenetic assessments (R=0.54). Patients with complex karyotypes identified by lcWGS exhibited significantly shorter overall and relapse-free survival, closely mirroring outcomes defined by conventional karyotyping and underscoring the value of lcWGS for risk stratification. Median turnaround time from sample receipt to bioinformatics interpretation was approximately 34 hours, enabling delivery of actionable karyotype results within 72 hours. These findings establish lcWGS as a rapid, reproducible, and accurate platform for detecting clinically relevant chromosomal abnormalities, addressing a critical need for timely risk stratification and treatment initiation in AML.Keywords
This publication has 32 references indexed in Scilit:
- Impact of Cytogenetic Response to Therapy on Long‐Term Survival in Acute Myeloid LeukemiaAmerican Journal of Hematology, 2025
- Real-time genomic characterization of pediatric acute leukemia using adaptive samplingLeukemia, 2025
- Genome profiling with targeted adaptive sampling long-read sequencing for pediatric leukemiaBlood Cancer Journal, 2024
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic NeoplasmsLeukemia, 2022
- Application of long-read sequencing to the detection of structural variants in human cancer genomesComputational and Structural Biotechnology Journal, 2021
- CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trialThe Lancet Haematology, 2021
- Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)Annals of Hematology, 2017
- Oxford Nanopore MinION Sequencing and Genome AssemblyGenomics, Proteomics & Bioinformatics, 2016
- Section E6.1–6.4 of the ACMG technical standards and guidelines: chromosome studies of neoplastic blood and bone marrow–acquired chromosomal abnormalitiesGenetics in Medicine, 2016
- Integrative genomics viewerNature Biotechnology, 2011